Search clinical trials for: Dalfampridine

Total 37 results

Acorda Therapeutics

Completed

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Acorda Therapeutics

Completed

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Ischemic Stroke

United States
Washington University School of Medicine
Acorda Therapeutics

Completed

Ampyra for Optic Neuritis in Multiple Sclerosis

Multiple Sclerosis | Optic Neuritis

United States
Acorda Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. (MILESTONE℠)

Post-Ischemic Stroke

United States, Canada
Acorda Therapeutics

Terminated

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine. (MILESTONE℠)

Post-ischemic Stroke

United States, Canada
MGH Institute of Health Professions

Not yet recruiting

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis (AmpPT)

Multiple Sclerosis

United States
UCB Biopharma SRL

Not yet recruiting

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis (roMyG)

Generalized Myasthenia Gravis
Brigham and Women's Hospital

Completed

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults (APIGLOSS)

Sleep Apnea, Obstructive

United States
Hospital for Special Surgery, New York

Active, not recruiting

Use of Dalfampridine in Primary Lateral Sclerosis

Motor Neuron Disease, Upper

United States
Oregon Health and Science University
Acorda Therapeutics

Completed

Dalfampridine for Imbalance in Multiple Sclerosis

Multiple Sclerosis | Fatigue

United States
Acorda Therapeutics

Completed

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Renal Insufficiency

United States
Acorda Therapeutics

Completed

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Cerebral Palsy (CP)

United States
John Elfar

Not yet recruiting

4-aminopyridine for Skin Wound Healing

Wounds and Injuries | Wound Heal | Wounds | Wound of Skin

United States
State University of New York at Buffalo

Completed

Effects of Dalfampridine on Cognition in Multiple Sclerosis

Multiple Sclerosis

United States
VA Office of Research and Development

Completed

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

Multiple Sclerosis | Fatigue | Internuclear Ophthalmoplegia

United States
Neuro-Ophthalmologic Associates, PC
Acorda Therapeutics

Completed

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Ampyra)

Non Arteritic Ischemic Optic Neuropathy

United States
D'Youville College
University at Buffalo; Acorda Therapeutics

Completed

Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis

Multiple Sclerosis
University of Florida
Acorda Therapeutics

Completed

Dalfampridine and Gait in Spinocerebellar Ataxias

Spinocerebellar Ataxias Type 1 | Spinocerebellar Ataxias Type 2 | Spinocerebellar Ataxias Type 3 | Spinocerebellar Ataxias Type 6

United States
Johns Hopkins University
Acorda Therapeutics

Completed

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Neuromyelitis Optica | Transverse Myelitis | Idiopathic Transverse Myelitis | Myelitis NOS

United States
European University of Lefke

Completed

Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

Hereditary Spastic Paraplegia

Cyprus
Milton S. Hershey Medical Center

Terminated

A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma

Nerve Injury

United States
Columbia University

Completed

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

Spinal Muscular Atrophy

United States
Acorda Therapeutics
Prometrika, LLC; BCS Consulting, Inc.

Completed

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Ain Shams University

Recruiting

Dalfampridine in Egyptian Patients With Multiple Sclerosis

Multiple Sclerosis

Egypt
Brown, Theodore R., M.D., MPH
Acorda Therapeutics

Completed

A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis

Multiple Sclerosis

United States
Sheba Medical Center

Unknown

Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS

Multiple Sclerosis

Israel
Biogen

Terminated

Fampridine Pregnancy Exposure Registry

Multiple Sclerosis | Pregnancy

France
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
University of Zurich

Unknown

Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis (FAMPKIN)

Multiple Sclerosis

Switzerland
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation... and other collaborators

Completed

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

Spinal Cord Injury

United States
Shirley Ryan AbilityLab
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Effects of 4-AP on Functional SCI Recovery

Spinal Cord Injury

United States
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy

Search clinical trials for: Dalfampridine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations